Citation: Villani E, Massaro D, Scaramuzzi M, Hamrah P, Medeiros FA, Nucci P. Decade-Long profile of imaging biomarker use in ophthalmic clinical trials. Invest Ophthalmol Vis PURPOSE. The purpose of this study was to investigate the use of imaging biomarkers in published clinical trials (CTs) in ophthalmology and its eventual changes during the past 10 years.
T he National Institutes of Health Biomarkers Definitions
Working Group defined biomarker as ''a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.'' 1 More than 10 years ago, in the white paper titled ''Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products,'' 2 the Food and Drug Administration recognized the critical role of biomarkers in drug development.
At present, there is broad consensus among researchers and regulatory agencies regarding the importance of biomarkers to translate scientific concepts into diagnostic and therapeutic approaches and technologies. 3 They represent an essential set of tools for accelerating basic science, drug discovery, and medical product development as well as improving clinical care. 3 Biomarkers are generally used for two main indications in clinical research. First, to select and stratify the study population (diagnostic, prognostic, and predictive biomarkers) and second, to replace true clinically relevant endpoints (surrogate endpoints) predicting the clinical benefit or harm of interest. 1, 4, 5 The use of biomarkers as surrogate endpoints in very early phases of clinical trials (CTs) to provide proofs of concept is of obvious utility. However, their inclusion in phase III CTs, where potential erroneous decisions based on invalid surrogate endpoints may have broad public health consequences, may pose specific and important challenges. 1, 6, 7 Medical imaging is increasingly used for screening, diagnosis, prognosis, evaluating the natural history of disease, or monitoring therapeutic efficacy. An imaging biomarker specifically uses a characteristic that is objectively observed and measured using an imaging device. The potential advantages of this approach are the chance to minimize subjective bias and inaccuracy as a result of unclear measurements, the ability to reveal subtle subclinical features or changes, and the opportunity to have blinded, standardized, and centralized evaluation of the images. [8] [9] [10] [11] The past 2 decades have seen a revolution in ophthalmic imaging, with a near exponential rise in peer-reviewed publications relating to clinical applications of new imaging modalities. 12 More important, this revolution has now reached CT design in ophthalmology. 11 Thus, we hypothesized that increased usage of imaging biomarkers in ophthalmic clinical research has occurred during the past 10 years. The purpose of this observational retrospective study was to verify this hypothesis, analyzing the use of imaging biomarkers in published CTs in ophthalmology and its relative utility during the past decade.
METHODS
We searched Medline through PubMed for CTs on cornea, glaucoma, and retina published in three different time periods from 2005 to 2016. Using filter tools provided by the website, we selected ''Clinical trial'' OR ''Randomized controlled trial'' as article type; ''from 2005/07/01 to 2006/06/30,'' ''from 2010/ 07/01 to 2011/06/30,'' and ''from 2015/07/01 to 2016/06/30'' as publication dates; and ''Cornea OR Glaucoma OR Retina'' as keywords. Two investigators (DM, MS) independently analyzed the full text of each paper and assessed the inclusion and exclusion of trials on the basis of topic (related to cornea, glaucoma, or retina), of article type (adherent to the World Health Organization definition of Clinical Trial), 13 and of language (we included English-language papers only). Disagreements were settled by discussion with a third investigator (EV).
Data collected for each included article consisted of the following features: Digital Object Identifier (DOI) of the article, publication timeframe (2005-2006, 2010-2011 or 2015-2016) , phase (I/II, III, IV, or trials on procedures), subspecialty (cornea, glaucoma, or retina), location (geographical area of the coordinating site), compliance with Consolidated Standards for Reporting Trials (CONSORT) guidelines 14 (yes if >12 items were fully reported; no if <12 items were fully reported), and impact factor (impact factor of the journal in which the study was published). 15 Moreover, articles were analyzed to detect the use of imaging biomarkers in general (yes or no), imaging diagnostic biomarkers (yes or no), imaging prognostic biomarkers (yes or no), imaging predictive biomarkers (yes or no), imaging surrogate primary endpoints (yes or no), and imaging surrogate secondary endpoints (yes or no) and to assess the use of a centralized reading center (RC). Biomarker types were defined on the basis of the Food and Drug Administration-National Institutes of Health BEST Resource. 5 Statistical analysis was conducted with commercial software (SPSS for Windows, version 21.0; SPSS Sciences, Chicago, IL, USA). Categorical data were expressed as ''ratios (percentages),'' impact factor as mean 6 standard deviation. Changes over the three timeframes were analyzed by linear-by-linear association trend test. Percentages were compared by v 2 test (with appropriate number of degrees of freedom, depending on contingency table size), and the impact factor was compared by Mann-Whitney U test (between two groups) or by Kruskal-Wallis test (more than three groups). The a level (type I error) was set at 0.05. Table 1 ). The 478 excluded articles included 70 that were out of scope, 332 studies other than clinical trials, and 76 written in languages other than English.
RESULTS
The percentage of phase IV CTs and trials on procedures (275 of 652 [42.2%] and 231 of 652 [35.4%], respectively) was significantly higher than phase I/II or III trials (87 of 652 [13.3%] and 59 of 652 [9.0%], respectively); P < 0.001.
Comparing the clinical trial phase distribution over the three timeframes studied, we found a progressive increase in phase III CTs (2 of In this analysis, the published CTs including imaging biomarkers were 302 of 652 (46.3%). Tables 5 and 6 report, respectively, the most commonly used imaging devices and the imaging parameters most frequently used as biomarkers.
Over the three timeframes, we found a significant time- (Table 7) .
Early-phase CTs (phases I/II and III) showed a significant increase over time in the use of biomarkers for patient selection and stratification (including predictive, diagnostic Although 30 of 59 (50.8%) of phase III CTs used secondary surrogate imaging endpoints, we found only 3 of 59 (5.1%) phase III CTs including primary surrogate imaging endpoints: two on retina 16, 17 (macular thickness by optical coherence tomography [OCT] and lesion enlargement by fundus autofluorescence) and one on glaucoma 18 
DISCUSSION
The inclusion of imaging biomarkers in ophthalmic clinical research shows great promise and, on the basis of our data, these tools are included in almost half of the ophthalmic clinical trials published in the past 10 years. We found a I-II  5  36  24  65  III  1  16  33  50  IV  36  26  18  80  Trials on procedures  14  17 15 46 I-II  7  7  2  16  III  0  0  4  4  IV  19  22  19  60  Trials on procedures  40  36  47  123 significantly increasing use of imaging biomarkers in general as tools for patient selection and stratification (mostly diagnostic biomarkers) and as secondary surrogate endpoints. The large use of imaging biomarkers requires efforts aimed to their standardization, rigorous validation, and adequate use as part of high-quality and well-designed clinical studies as well as the utility of centralized RCs.
For early-phase studies, we reported a high increase in the percentage of CTs including imaging biomarkers, other than surrogate endpoints, in the past 10 years. Given regulatory and broad public health implications, the inclusion of primary surrogate imaging endpoints in phase III CTs has particular challenges, starting from the need for appropriate validation and qualification processes. As recently discussed by Wagner and Atkinson, 6 validation is the process of assessing the assay and its measurement performance characteristics and determining the range of conditions under which the assay will give reproducible and accurate data. Qualification, essential for surrogate endpoints, is the ''fit for purpose'' process aimed to demonstrate not only the link between a biomarker and a biological process but also that, ''within the stated context of use, a biomarker can be relied upon to have a specific interpretation and application in drug development and regulatory review.'' 4, 19 Furthermore, the use of imaging data as a primary endpoint in CTs requires particular attention to the need for trial-specific imaging process standards and for centralized, blinded imaging interpretation by RCs. 11 Centralized RCs guarantee collection of high-quality, standardized, and unbiased imaging data that are uniform across different clinical sites and masked to any clinical information. 20 Our data showed that CTs including imaging biomarkers assessed by centralized RCs were published in journals with a higher impact factor, suggesting that these research articles might obtain broader consideration. Moreover, RCs were mostly used in phase III CTs, which have more stringent regulatory requirements. Our failure to demonstrate a timerelated increase in the use of RCs suggests the need for huge commitment to the improvement of imaging biomarkers usage in clinical research. Number of papers  68  71  69  208  Phases   I-II  0  2  4  6  III  1  3  1  5  IV  53  45  37  135  Trials on procedures  14  21 27 62 Major efforts are needed to avoid the potential consequences of biomarker misuse or of the choice of invalid surrogate endpoints (ranging from the approval of a therapy favorably affecting the surrogate but not the clinical endpoint 21 to the failure of trials because of underpowering or poor patients selection 22 ). On the other hand, it is essential to allow imaging biomarkers to play a central role in supporting new drugs development and approval. Our data highlight these concerns, showing a persistent almost total lack of primary surrogate imaging endpoints in phase III CTs to date.
In our analysis, phase IV CTs showed a significantly higher presence of primary surrogate imaging endpoints (27.2%) . This finding may be because of the very high utility of this approach in postmarketing trials, which require less stringent validation and allow a less risky and more pioneering use of biomarkers to demonstrate their proof of concept. However, standardization and validation are also important in phase IV CTs because, as stated by Ioannidis in the controversial article titled ''Why Most Published Research Findings Are False,'' 23 ''the greater the flexibility in designs, definitions, outcomes, and analytical modes in a scientific field, the less likely the research findings are to be true.'' 23 The subspecialty-based analysis revealed that retinal CTs had the highest prevalence of every type of imaging biomarker, mainly because of the wide use of OCT (included in 27.7% of all the analyzed CTs and in 63.1% of CTs on retina). Fujimoto and Swanson recently highlighted the dramatic growth in OCTrelated publications during the past years, indicating the extent of scientific and clinical progress due to this technology. 24 Moreover, in the past 10 years, the pivotal role of OCT imaging in the development of anti-angiogenic therapies for the treatment of macular diseases provided a remarkable example of the potentials of synergy between imaging technologies and pharmaceutical research in ophthalmology. 25 Another interesting result is that articles reporting retinal CTs showed the most frequent use of RCs and the highest CONSORT compliance. Given the well-known suboptimal adherence to these standards in published trials, [26] [27] [28] we arbitrarily defined as compliant the articles fully reporting more than one half of the items included in the CONSORT checklist. 14 Although not a direct measure of the intrinsic quality of a study, reporting quality provides the reader with useful tools for the evaluation of its validity.
The present study provides new preliminary information on ophthalmic implications of a hot topic in clinical research. However, our study has some limitations. The methodology used for search and inclusion of articles is partially arbitrary and provided a relatively small sample of articles, particularly of phase III trial reports. Moreover, as it is based on already published and indexed reports, this study does not include the most recently designed CTs and might not fully reflect the very last state of imaging use in clinical research.
In conclusion, this study shows a large use of imaging biomarkers in published CTs in ophthalmology and an increase in the use of imaging biomarkers for patient selection and stratification and as secondary surrogate endpoints. Additional efforts are needed to improve validation of these tools to overcome infrastructural, economic, and cultural obstacles, 29 optimizing the use of imaging biomarkers in clinical research and allowing more frequent use of imaging surrogate primary endpoints to support new drug development and approval. 
